SCIENTIFIC Literature

Case Report

A Case Report of Angelman Syndrome

Carlos Maragoto-Rizo¹, Irene González-González², Arturo Rodríguez-López^{1*}, Lorena Gil-Navarro², Héctor Vera-Cuesta¹, Lázaro Gómez- Fernández¹, María de los Ángeles-Ortega¹, Reinaldo Galvizu-Sánchez¹, Alejandro A Peláez-Suárez¹, Judith González-González¹ and Marilyn Zaldívar-Bermúdez¹

¹International Center of Neurological Restoration (CIREN), Cuba

²Department of Medical Science, University of Medical Science, Cuba

ARTICLE INFO

Received Date: June 30, 2020 Accepted Date: July 22, 2020 Published Date: July 22, 2020

KEYWORDS

Autism Epilepsy Angelman Syndrome

Copyright: © 2020 Arturo Rodríguez-Neurological Disorders & López. Epilepsy Journal. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Citation for this article: Carlos Maragoto-Rizo, Irene González-González, Arturo Rodríguez-López, Lorena Gil-Navarro, Héctor Vera-Cuesta, Lázaro Gómez- Fernández, María de los Ángeles-Ortega, Reinaldo Galvizu-Sánchez, Alejandro A Peláez-Suárez, Judith González-González and Marilyn Zaldívar-Bermúdez. A Case Report of Angelman Syndrome. Neurological Disorders & Epilepsy Journal. 2020; 3(2):132

Corresponding author:

Arturo Rodríguez-López, International Center of Neurological Restoration (CIREN), Cuba, Email: r2d2rodlop@gmail.com

ABSTRACT

We describe a case of a female pediatric patient showing recurrent seizures, socialization problems and speech development delay. She was born preterm, due to fetal heart rate alterations and spent a few days in neonatal intensive care. She has presented evolutionary global neurodevelopment delay and from the first year of life, she presented sleep disorders referred to as difficulties in initiating sleep and frequent waking up with irritability. She shows 2 kinds of seizures referred to as oneside of the face and the ipsilateral arm contractions and brief falls of the head and trunk backwards. Complementary test were done, such as Video/EGG recording, neuropsychological evaluation and genetic studies to the patient and her mother.

INTRODUCTION

Angelman Syndrome (AS)is a neurodevelopmental disorder caused by an absent or non-functioning maternal allele of chromosome 15q11-q13 [1]. These disorder was first described in 1965 by Harry Angelman [2]. AS is a severe neurodevelopmental disorder, with a prevalence estimate ranging from 1 in 20,000 to 1 in 12,000 [3]. The typical AS phenotype is characterized by Intellectual Disability (ID), lack of speech, hyperactivity, ataxic gait, microcephaly, sleep disturbances, frequent laughter/smiling and an apparently happy demeanor [4-6], high prevalence of epilepsy, and feeding problems [6]. Epilepsy occurs in 80% of cases, usually involving multiple seizure types and starting in early childhood [7,8].

High rates of autistic symptoms are also reported, estimating the prevalence of Autism Spectrum Disorder (ASD) from 24 to 81%9.AS could be due to UBE3A mutations, uniparental disomy and imprinting defects [2,6], but deletions are the predominant cause and are found in 68-75% of patients [6]. Otherwise, the spectrum of the 15q13.3 deletion syndrome overlaps that of AS, sharing features such as epilepsy/abnormal EEG, hyperactivity and widely spaced teeth [10]. CHRNA7 encodes $\alpha7$ subunit of neuronal nicotinic acetylcholine receptor protein, among several, it is expressed the pre and post-synaptic region where it regulates both GABA and glutamate neurotransmitters in the hippocampus, it was also detected in the rat striatum dopaminergic neurons. CHRNA7 involves in Ca2+ regulation, which then affect several Ca2+ dependent pathways, suggested as the prime candidate for the seizure phenotype [11].



SCIENTIFIC LITERATURE

Interestingly, OTU domain-containing deubiquitinating enzyme (OTUD7A) localized within the recurrent 15q13.2q13.3 deletion encodes for a deubiquitination enzyme expressed in the brain. Deubiquitination enzymes generally oppose the action of ubiqutin ligases, such as UBE3A, by specifically cleaving ubiquitin linkages. Possibly, a heterozygous deletion of OTUD7A leads to a disruption of the ubiquitination pathway and contributes to the phenotypic overlap between patients with AS and patients with the 15q13.3 deletion syndrome [10,11]. Considering the potential upcoming treatments in AS, it is important to get a more detailed view of all the health issues in AS, with a focus on epilepsy and neurodevelopmental outcomes as these are likely to be the target of future interventions [12,13].

CASE PRESENTATION

The patient is a 4 years-old female and first sibling of a tow member offspring from parents not related by blood. The mother was 35 years old and the father 36 years old at the time of conception. She was born preterm by cesarean section at 33.5 weeks gestation due to fetal heart rate alterations causing termination of pregnancy. She spent 23 days in neonatal intensive care, the first 18 days with intermittent assisted ventilation, and was diagnosed with respiratory distress in the newborn. She has presented evolutionary global neurodevelopmental delay. With rehabilitation treatment she got cephalic support at 6 months, clumsy prehension at 8 months, digital clamp at 12 months, seating by herself at 12 months, putting objects in her mouth at 14 months, standing and first steps at 24 months, more stable at 3 years, first words at age 3. She does not say simple sentences and does not control sphincters. Also she has problems with socialization with parents and other children, that improved with early stimulation. From the first year of life, she presents sleep disorder referred to as difficulties in initiating sleep and frequent waking up with irritability. At two years of age, she began to have seizures referred to as one-side of the face and the ipsilateral arm contractions, approximately 12 times a day, with a weekly frequency, always associated with febrile processes. Since then she was treated with levetiracetan with improvement in the severity. Later the patient presented other forms of seizures characterized by brief falls of the head and trunk backwards, which occurred less frequency, approximately 5 daily. After

these events, it was associated with lamotrigine with improvement in the frequently of both events. According to her mother, at that time, she was showing a daily occurrence of 7 seizures of the first kind and 2 of the second kind as described above. In addition, she showed great interest for water-related activities like swimming, take a bath or watch the rain. The general physical examination reports a smiley face with dysmorphias such as a small forehead, prominent tongue, wide mouth, spaced teeth and prominent jaw.

In the neurological examination, we reported a mindful patient, who interacts with the examiner, has visual and sound followup, smiles spontaneously during the whole exploration, throws kisses and comply with simple orders. She does not control sphincters. She understands the meaning of yes and no, give and take. She communicates with vocalizations, emits few words (mom, dad).She goes up and down the stairs with support, without alternating her feet. She does not jump, and she cannot stand on one foot. Handles objects awkwardly, has a clumsy digital clamp. She also shows ataxic gait with flexed arms, with mouth excessive drooling. strabismus. open hypopigmented skin, light hair and eye color and Hyperactive lower extremity deep tendon reflexes.

An electroencephalogram was performed which resulted: during the vigil a record was obtained with eyes open all the time, in these conditions the proper organization of the basic activity according to age was not identified. A notable global slow anomaly was found in the temporal and frontal regions of the left hemisphere. An active paroxysmal interictal disorder was fond that focuses on the anterior temporal territory of the left hemisphere. Prolonged monitoring evolutionary Video/EEG recording was performed using Micromed Software System Plus Evolution Equipment, 32 extracranial recording electrodes were placed. In 24 hours of continuous monitoring Video-EEG without reduction of anti-epileptic medication.

This study shows a significant decrease in the frequency of discharge of the interictal electroencephalographic epileptiform patterns characteristic of Angelman Syndrome: rhythmic delta pattern anterior regions, posterior theta pattern and epileptiform discharges in posterior regions that were significantly exacerbated with ocular closure. The Predominant ictal activity in these 24 hours record were the generalized non-motor crisis with poli-spike 3Hz pattern corresponding to a

Neurological Disorders & Epilepsy Journal

typical absence seizure pattern which one were unseen by the mother or the nurse, and myoclonic seizures of one-side of the face and the ipsilateral arm. Also generalized atonic seizures of the upper limbs and trunk where found.

In the neuropsychological evaluation, a performance corresponding to a developmental age of approximately 18 months and a developmental coefficient of 35, which corresponds to a severe level of psychomotor development, influenced by motor, language and behavioral limitations, was shown during the neuro-psychology session, with greater affectation of language and behavior.

DISCUSSION

Background

• Prenatal: Fetal suffering.

• Perinatal: preterm, spent 23 days in neonatal intensive care and was diagnosed with respiratory distress in the newborn.

• Postnatal: Neurodevelopmental delay, sleep disorder and socialization problems

Clinical findings

- Neurodevelopmental delay
- Seizures described before
- Dysmorphic according to Algelman Syndrome.
- Clinical Characteristics according to Algelman
 Syndrome

Complementary tests

 -Video/EGG recording: This study shows patterns characteristic of Angelman Syndrome, the electrical characterization of the two kinds of seizures described above and the electro-clinical evidence of typical absence seizure unnoticed until these recording.

 In the neuropsychological evaluation: showing a severe level of psychomotor development, influenced by motor, language and behavioral limitations

Genetic studies

1. A normal karyotype study of the patient and her mother

2. Fluorescence in Situ Hybridization (FISH) study showing amicrodeletion of the chromosome 15q11.2-13.3 region which extends about 4.8Mb involving the region of UBE3A, OTUD7Aand CHRNA7 genes. The same study was also performed on the mother and no alteration were found.

TREATMENT

An intensive, personalized, comprehensive, multidisciplinary and interdisciplinary neurorestaurative treatment program was also incorporates, which included:

Physical rehabilitation, special education and speech therapy program. Non- invasive brain stimulation, 20 sessions of electrical mode, language stimulation protocol. Pharmacological readjustment: change of anti-epileptic medication, given by the gradual withdrawal of lamotrigine and the incorporation of valproic acid because the typical absence seizure.

CONCLUSION

This is a typical case of Angelman Syndrome, having the most common characteristics. The prenatal, perinatal and postnatal background and the clinical findings are according with this syndrome and with the complementary exams for example: Video/EEG recording the patterns characteristic of Angelman Syndrome and the genetic test that was interpreted as a de novo microdeletion of the region of UBE3A gene and a 15g13.3 deletion syndrome. Early stimulation help with the socialization issues and the characteristics of the ASD were not predominant in our patient but may be common in this syndrome. In addition, the speech developmental delay was one of the problems that make the patents to search for medical attention, fact that is very frequent. The disorder in question is very uncommon, it might be on the interest to the scientific community, health care professionals and medical science students. Angelman Syndrome do not pose a severe risk for the patient's live but indeed heavily affect its quality and also the life of the parents.

REFERENCES

- Buiting K, Williams C, Horsthemke B. (2016). Angelman syndrome-insights into a rare neurogenetic disorder. Nat Rev Neurol. 12: 584-93.
- Angelman H. (1965). "Puppet" children. A report on three cases. Dev Med Child Neurol. 7: 681-683.
- Buiting, K. et al. (2015). Clinical utility gene card for: Angelman syndrome. Eur J Hum Genet. 23.
- 4. Dagli Al, Mueller J, Williams CA. (2015). Angelman syndrome. In: Gene Reviews.

SCIENTIFIC LITERATURE

- Bakke KA, Howlin P, Retterstøl L, Kanavin ØJ, Heiberg A, et al. (2018). Effect of epilepsy on autism symptoms in Angelman syndrome. Molecular Autism.
- Bindels-de Heus KGCB, Mous SE, ten Hooven-Radstaake M, et al. (2019). An overview of health issues and development in a large clinical cohort of children with Angelman syndrome. Am J Med Genet Part A. 1-11.
- Bird LM. (2014). Angelman syndrome: review of clinical and molecular aspects. Appl Clin Genet. 7: 93-104.
- Thibert RL, Conant KD, Braun EK, Bruno P, Said RR, et al. (2009). Epilepsy in Angelman syndrome: a questionnairebased assessment of the natural history and current treatment options. Epilepsia. 50: 2369-2376.
- Richards C, Jones C, Groves L, Moss J, Oliver C. (2015). Prevalence of autism spectrum disorder phenomenology in genetic disorders: a systematic review and meta-analysis. Lancet Psychiatry. 2: 909-916.

- Barøy T, Misceo D, Braaten Ø, Helle JR, Fannemel M, Strømme P, et al. (2010). A de novo 15q13.2q13.3 deletion in a boy with an Angelman syndrome like phenotype. European Journal of Medical Genetics. 53: 221-224.
- 11. Alsagob M, Salih MA, Hamad MHA, Al-Yafee Y, Al-Zahrani J, et al. (2019). First report of two successive deletions on chromosome 15q13 cytogenetic bands in a boy and girl: additional data to 15q13.3 syndrome with a report of high IQ patient. Molecular Cytogenetics. 12: 21.
- Beaudet AL, Meng L. (2006). Gene-targeting pharmaceuticals forsingle-gene disorders. Human Molecular Genetics, 25: R18-R26.
- Tan WH, Bird LM. (2016). Angelman syndrome: Current and emergingtherapies in 2016. American Journal of Medical Genetics. Part C,Seminars in Medical Genetics. 172: 384-401.